Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A retrospective study assessing the characterization of the immunologic constituents of the immune TME (iTME) and efficacy of Elotuzumab, Lenalidomid and Dexamethasone in patients with relapse multiple myeloma

Next Previous
Search
Trial Profile

A retrospective study assessing the characterization of the immunologic constituents of the immune TME (iTME) and efficacy of Elotuzumab, Lenalidomid and Dexamethasone in patients with relapse multiple myeloma

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 01 Feb 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dexamethasone (Primary) ; Elotuzumab (Primary) ; Lenalidomide (Primary)
  • Indications Multiple myeloma
  • Focus Pharmacodynamics; Therapeutic Use

    • Most Recent Events

    • 01 Feb 2022 New trial record
    • 14 Dec 2021 Results presented at the 63rd American Society of Hematology Annual Meeting and Exposition

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top